Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab

American Journal of Cardiology

Volumn 90, Issue 11, 2002, Pages 1198-1203

  Mukherjee, Debabrata ^a   Gurm, Hitinder ^b   Tang, W H Wilson ^b   Roffi, Marco ^b   Wolski, Kathy ^b   Moliterno, David J ^b   Guetta, Victor ^c   Ardissinio, Diego ^e   Bode, Christopher ^d   Steg, Gabriel ^f   Lincoff, A Michael ^b   Topol, Eric J ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c SHEBA MEDICAL CENTER   (Israel)

^d UNIVERSITY OF FREIBURG   (Germany)

^e MAGGIORE HOSPITAL   (Italy)

^f BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOLYTIC AGENT; RETEPLASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; FIBRINOLYTIC THERAPY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; ST SEGMENT ELEVATION; THROMBOCYTOPENIA;

AGED; ANTIBODIES, MONOCLONAL; CORONARY ARTERY BYPASS; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RECOMBINANT PROTEINS; RISK FACTORS; SURVIVAL ANALYSIS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 0036890519     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02834-5     Document Type: Article

References (21)

1. Labinaz M., Sketch M.H. Jr, Ellis S.G., Abramowitz B.M., Stebbins A.L., Pieper K.S., Holmes D.R. Jr, Califf R.M., Topol E.J. Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapy. Am Heart J. 141:2001;469-477.
2. Grines C.L., Booth D.C., Nissen S.E., Gurley J.C., Bennett K.A., O'Connor W.N., DeMaria A.N. Mechanism of acute myocardial infarction in patients with prior coronary artery bypass grafting and therapeutic implications. Am J Cardiol. 65:1990;1292-1296.
3. Kavanaugh K.M., Topol E.J. Acute intervention during myocardial infarction in patients with prior coronary bypass surgery. Am J Cardiol. 65:1990;924-926.
4. Lee K.L., Woodlief L.H., Topol E.J., Weaver W.D., Betriu A., Col J., Simoons M., Aylward P., Van de Werf F., Califf R.M. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation. 91:1995;1659-1668.
5. Califf R.M., Pieper K.S., Lee K.L., Van de Werf F., Simes F.J., Armstrong P.W., Topol E.J. Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. Circulation. 101:2000;2231-2238.
6. American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, Texas: American Heart Association, 2001.
7. Campeau L., Enjalbert M., Lesperance J., Bourassa M.G., Kwiterovich P. Jr, Wacholder S., Sniderman A. The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. N Engl J Med. 311:1984;1329-1332.
8. Cameron A., Kemp H.G. Jr, Shimomura S., Santilli E., Green G.E., Hutchinson J.E. III, Mekhjian H.A. Aortocoronary bypass surgery a 7-year follow-up . Circulation. 60:1979;9-13.
9. Campeau L., Lesperance J., Hermann J., Corbara F., Grondin C.M., Bourassa M.G. Loss of the improvement of angina between 1 and 7 years after aortocoronary bypass surgery correlations with changes in vein grafts and in coronary arteries . Circulation. 60:1979;1-5.
10. Johnson W.D., Kayser K.L., Pedraza P.M. Angina pectoris and coronary bypass surgery patterns of prevalence and recurrence in 3105 consecutive patients followed up to 11 years . Am Heart J. 108:1984;1190-1197.
11. Kleiman N.S., Berman D.A., Gaston W.R., Cashion R., Roberts R. Early intravenous thrombolytic therapy for acute myocardial infarction in patients with prior coronary artery bypass grafts. Am J Cardiol. 63:1989;102-104.
12. Anonymous. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation 2000;101:2788-2794.
13. Antman E.M., Giugliano R.P., Gibson C.M., McCabe C.H., Coussement P., Kleiman N.S., Vahanian A., Adgey A.A., Menown I., Rupprecht H.J., et al. Abciximab facilitates the rates and extent of thrombolysis results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial. The TIMI 14 Investigators . Circulation. 99:1999;2720-2732.
14. Topol E.J. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition the GUSTO V randomised trial . Lancet. 357:2001;1905-1914.
15. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy, and safety of tenecteplase in combination with enoxaparin abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-613.
16. The GUSTO Investigators . An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682.
17. Cura F.A., Bhatt D.L., Lincoff A.M., Kapadia S.R.L.', Allier P.L., Ziada K.M., Wolski K.E., Moliterno D.J., Brener S.J., Ellis S.G., Topol E.J. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions. Circulation. 102:2000;28-34.
18. Mak K.H., Challapalli R., Eisenberg M.J., Anderson K.M., Califf R.M., Topol E.J. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. Am J Cardiol. 80:1997;985-988.
19. Roffi M., Bhatt D., Mukherjee D., Chew D., Ziada K., Prosper D., Ellis S., Topol E. Stents and glycoprotein IIb/IIIa blockade have no salutary effect on 30-day outcome following percutaneous interventions of coronary bypass grafts. J Am Coll Cardiol. 37:2001;68A.
20. Hong M.K., Mehran R., Dangas G., Mintz G.S., Lansky A., Kent K.M., Pichard A.D., Satler L.F., Stone G.W., Leon M.B. Are we making progress with percutaneous saphenous vein graft treatment? A comparison of 1990 to 1994 and 1995 to 1998 results. J Am Coll Cardiol. 38:2001;150-154.
21. Margolis J.R., Morgensen L., Mehta S., Chen C.Y., Krauthamer D. Diffuse embolization following percutaneous transluminal coronary angioplasty of occluded vein grafts the blush phenomenon . Clin Cardiol. 14:1991;489-493.